Agomelatine improves symptoms of generalised anxiety disorder
Agomelatine improves symptoms of generalised anxiety disorder
Question:
Is agomelatine effective for people with generalised anxiety disorder?
Patients:
121 people, aged 18–65 years, with DSM-IV generalised anxiety disorder (69% female, mean age 42 years) (see online notes for exclusion criteria).
Setting:
Five centres in Finland and six centres in South Africa; time period not stated.
Intervention:
Agomelatine (n?=?63; 25–50 mg/day) or placebo (n?=?58) for 12 weeks. Agomelatine dose was increased from 25 to 50 mg/day if there was an insufficient response after 2 weeks. This was done in a blinded fashion, using a dose adjustment algorithm.
Outcomes:
Primary outcome: overall anxiety (HAM-A). Secondary outcomes: response (?50% reduction in HAM-A score); somatic anxiety, psychic anxiety, severity of illness, sleep and disability symptoms (HAM-A subscales, Clinical Global Impressions Scale, Leeds Sleep Evaluation Questionnaire and Sheehan Disability Scale); discontinuation effects in the week after discontinuation (Discontinuation Emergent Signs and Symptoms scale (DESS)).
54-54
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Lopes, Antonio T.
86e7d3af-5d27-4d6e-998a-eeee40f171f1
2009
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Lopes, Antonio T.
86e7d3af-5d27-4d6e-998a-eeee40f171f1
Baldwin, David S. and Lopes, Antonio T.
(2009)
Agomelatine improves symptoms of generalised anxiety disorder.
Evidence-Based Mental Health, 12 (2), .
(doi:10.1136/ebmh.12.2.54).
Abstract
Question:
Is agomelatine effective for people with generalised anxiety disorder?
Patients:
121 people, aged 18–65 years, with DSM-IV generalised anxiety disorder (69% female, mean age 42 years) (see online notes for exclusion criteria).
Setting:
Five centres in Finland and six centres in South Africa; time period not stated.
Intervention:
Agomelatine (n?=?63; 25–50 mg/day) or placebo (n?=?58) for 12 weeks. Agomelatine dose was increased from 25 to 50 mg/day if there was an insufficient response after 2 weeks. This was done in a blinded fashion, using a dose adjustment algorithm.
Outcomes:
Primary outcome: overall anxiety (HAM-A). Secondary outcomes: response (?50% reduction in HAM-A score); somatic anxiety, psychic anxiety, severity of illness, sleep and disability symptoms (HAM-A subscales, Clinical Global Impressions Scale, Leeds Sleep Evaluation Questionnaire and Sheehan Disability Scale); discontinuation effects in the week after discontinuation (Discontinuation Emergent Signs and Symptoms scale (DESS)).
This record has no associated files available for download.
More information
Published date: 2009
Identifiers
Local EPrints ID: 148101
URI: http://eprints.soton.ac.uk/id/eprint/148101
ISSN: 1362-0347
PURE UUID: c31ef972-16b4-4e02-ab05-05a9929e5109
Catalogue record
Date deposited: 27 Apr 2010 11:00
Last modified: 14 Mar 2024 02:38
Export record
Altmetrics
Contributors
Author:
Antonio T. Lopes
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics